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Abstract
JAK-STAT signalling is a main transduction pathway of cytokines and growth factors,
which  is  involved  in  several  biological  processes  including  cell  proliferation,  cell
differentiation, axon regeneration, apoptosis and inflammation. After spinal cord injury
several  cytokines activate the JAK-STAT pathway, thereby modulating several cell
responses. In this chapter we discuss how regulation of this signalling pathway could
improve motor recovery after injury by modulation of axon regeneration, neuropro‐
tection, glial scar formation, demyelination and inflammatory response. Studies with
gene over-expression,  gene deletion and in  vitro  approaches  will  be  discussed for
understanding  the  cell-specific  response  to  JAK-STAT signalling,  with  a  focus  on
preclinical treatment with IL6-family cytokines, hematopoietic cytokines and IL10.
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1. Introduction
Worldwide, an estimate of 180,000 cases of spinal cord injuries (SCI) occur yearly [1]. SCI results
in the complete or partial loss of motor and sensory functions below the lesion site. This type of
injury causes irreversible paralysis, chronic pain, loss of bladder, bowel and sexual function,
amongst others dysfunctions, impairing quality and increasing the cost of life [2, 3].
The pathology of SCI in mammals starts with an acute phase during the first days of injury,
which includes massive cell death and inflammatory response. The acute response is fol‐
lowed by a second phase during the first week after injury consisting of tissue replacement,
where the loss of cells is replaced by a glial scar. After the second week it finalizes with a third
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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phase which continues for months involving chronic tissue remodelling, remyelination and
circuit remodelling [4]. Although some spontaneous repair after SCI has been described in
mammals including humans, it contributes poorly to motor and functional recovery.
Progenitor cells proliferate and differentiate but mostly to glial cells while no neurogenesis
occurs [5, 6]. Besides there is only a partial axon regeneration and circuit remodelling response
that contribute to a limited compensatory recovery [2].
Several reviews have been published describing growth factors and cytokines that regulate
cell response in SCI [2, 7, 8]. Advancements using these factors to improve spinal cord repair
are being made, and preclinical treatments have been achieved by local delivery of growth
factors and by physiological delivery with i.v. or i.p. injections (intravenous or intraperito‐
neal, respectively) [2]. Between the plethora of signalling pathways activated in response to
tissue injury, the JAK-STAT signalling pathway is one of the main pathways that has been
extensively studied because of its broad effect on the response to injury. In this chapter, we
discuss the activation and role of JAK-STAT signalling in response to SCI and studies focused
on modulating JAK-STAT to improve motor recovery. First, we briefly describe the JAK-STAT
pathway components, followed by a discussion of its role in different cellular processes
including: axonal regeneration, neuroprotection, glial response and its effects on the inflam‐
matory response.
2. JAK-STAT signalling pathway
The JAK-STAT signalling pathway is involved in transmitting information from the extracel‐
lular milieu to gene promoters in the nucleus. The basic components of the JAK-STAT pathway
are depicted in Figure 1. Several cytokines, growth factors and even hormones signal through
the JAK-STAT pathway. Currently, there are 38 protein ligands and 36 cell surface receptor
combinations have been described [9]. Besides the several combinations of protein ligands and
receptor complexes, in mammals there are four JAK (Janus kinase) tyrosine kinases: JAK1,
JAK2, JAK3 and Tyk2 (Non-receptor tyrosine-protein kinase TYK2); and seven STAT (Signal
transducer and activator of transcription) transcription factors: STAT1, STAT2, STAT3, STAT4,
STAT5a, STAT5b and STAT6 [9].
Activation of the JAK-STAT pathway begins after ligand binding to the receptor subunits,
which forms homodimers, heterodimers or heteromultimers depending on the family
receptor (Table 1 presents ligands and receptors related to SCI). After multimerization,
intracellular transduction is initiated through the recruitment of JAK kinases. JAKs phosphor‐
ylate receptor subunits and STAT transcription factors. After tyrosine phosphorylation,
cytosolic STATs dimerize and are translocated to the nucleus to bind specific DNA regulato‐
ry sequences and regulate gene expression [10].
The JAK-STAT signalling pathway has different negative inhibitors. The most important
inhibitor for preclinical studies is the classical negative feedback loop of suppressor of cytokine
signalling (SOCS) proteins, which are target genes for STATs proteins and switch off JAK
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proteins. Over-expression or deletion of SOCS3, one of the eight mammalian SOCS proteins,
has been extensively used to modulate endogenous pathway activation [11–13].
Although it will not be discussed in this chapter, it has to be considered that ligands binding
to receptor complexes also activate other intracellular signalling cascades besides the JAK-
STAT pathway [10]. Phosphorylation of receptors induces activation of ERK1/2 and AKT
pathways. Moreover, STATs can also be activated independently to the canonical JAK-STAT
signalling pathway. Growth factor activation of RTKs (receptor tyrosine kinases) and
NRTKs (non-receptor tyrosine kinases) can activate STATs. Hormone and chemokine binding
to G protein–coupled receptors can also activate JAKs proteins to phosphorylate STATs [10].
Figure 1. Basic components of the JAK-STAT signaling pathway. After binding of cytokines, receptors multimerize
(violet boxes) recruiting to the membrane and activating JAK kinases (orange boxes) that initiate substrate phosphory‐
lation (letter P). STAT transcription factors (pink boxes) are phosphorylated, dimerized and transported to the nucleus.
STAT dimers regulate gene transcription. Among others, a classic target is SOCS that forms a negative feedback loop
inhibiting JAK function. Alternative signaling pathways (grey boxes) for JAK-STAT are JAK-receptor complex activa‐
tion of ERK1/2 and AKT pathways; STATs phosphorylation by RTKs, NRTKs or JAKs associated to G-coupled protein
receptors.
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3. JAK-STAT pathway activation in response to SCI
3.1. Cytokine expression in response to SCI
Before discussing the role of the JAK-STAT pathway in motor recovery, we will discuss the
endogenous expression of cytokines and activation of STAT proteins in response to SCI. The
upregulation of the IL6 family cytokines, IL6 (Interleukin 6), LIF (Leukemia inhibitory factor),
OSM (Oncostatin M), IL11 (Interleukin 11) and CNTF (Ciliary neurotrophic factor) have been
well characterized in response to SCI. Early IL6 and LIF upregulation has been detected in the
acute phase after SCI, with a peak of expression around 6–12 hpi (hours post-injury) and basal
levels at 4 dpi (days post-injury) [14, 15]. Different neural cell types contribute to IL6 and LIF
expression. It has been shown that IL6 has a broad cell type expression, being detected in
neurons, astrocytes and macrophages, while LIF is mainly expressed in meningeal astro‐
cytes [14]. IL6 mRNA expression correlates with IL6 protein levels analyzed in another study,
which detected an increase in IL6 concentration from 3 hours to 3 dpi [16]. In these studies the
upregulation of cytokines occurs in the surrounding area of the lesion site, around 1 or 2 mm
from the epicentre.
Early upregulation of OSM is also detected after SCI, with a strong peak at 6 hpi, but on the
contrary to IL6 and LIF, upregulation of OSM is still detected until 1 mpi (months post-
injury) [15]. IL11 and CNTF protein upregulation has also been detected after the acute phase.
A steady increase in protein levels has been detected during the first week of injury for IL11
and during the first month for CNTF. In both cases no later times were analyzed to deter‐
mine when the cytokines reached basal levels, therefore there is a possibility that they had an
extended upregulation [17, 18]. IL11 cell expression has not been analyzed; on the contrary, it
has been shown that CNTF has a chronic expression in glial cell types after spinal cord injury.
CNTF has been detected in oligodendrocytes during the first month and in astrocytes up to 4
mpi [18, 19]. This chronic expression of CNTF is more spatially restricted than the early
expressed cytokines IL6 and LIF, being detected only in the lesion borders [19].
Cytokine
family
Cytokine Receptors JAKs STATs Endogenous levels,
preclinical or
clinical trials
IL6 IL6 Gp130 –
IL6R
Jak1 STAT1-3 U/P
LIF Gp130 –
LIFR
Jak2 STAT3 U/P
CNTF Gp130 –
LIFR – CNTFR
Tyk2 STAT3 U/P
IL11 Gp130 –
IL11R
STAT3 U
OSM Gp130 – STAT3 U/P
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Cytokine
family
Cytokine Receptors JAKs STATs Endogenous levels,
preclinical or
clinical trials
LIFR
Hematopoietic G-CSF CSF3R Jak2 STAT3 P/C
GM-CSF CSF2Ra –
βcR
Jak2 STAT5a/b P/C
EPO EpoR or
EpoR-βcR
Jak2 STAT5a/b P/C
IL10 IL10 IL10Rα
– IL10Rβ
Jak1 – Tyk2 STAT1-3 P
Table 1. JAK-STAT ligands, receptors and transducers involved in spinal cord injury. Cytokines are shown with
associated receptors and JAK-STAT components. It is shown if cytokines are up-regulated in response to SCI (U) or if
they have been used in preclinical (P) or clinical (C) studies for spinal cord recovery.
3.2. JAK-STAT signalling in response to SCI
In concordance with the upregulation of cytokines in response to SCI, several studies have
characterized JAK-STAT pathway activation in spinal cord cells. Consistent with the transi‐
ent increase of IL6 concentration, in the same study it was detected an increase in gp130
dimerization and JAK1 phosphorylation [16]. As expected for the activation of the gp130/JAK1
axis, STAT1 and STAT3 are phosphorylated in response to SCI. pSTAT1 has an acute in‐
crease which reach basal levels at 2 dpi [20]. On the contrary, pSTAT3 has an extended increase
which differs between studies. An increase in pSTAT3 has been detected up to 7 dpi in some
studies [12, 16], while in another no basal levels were reached even after 2 weeks post-injury
(wpi) [21]. Nevertheless, all studies agree that STAT3 has a longer activation than STAT1.
Together with the temporal difference, protein localization suggests that STAT3 has a more
prominent role in regulating gene expression than STAT1 in cell response. While pSTAT3 has
been detected in neuron nuclei after spinal cord injury, pSTAT1 has been only detected in the
cytoplasm [16, 20].
STAT3 activation has been characterized in several spinal cord cell types. In the acute injury,
nuclear pSTAT3 is observed in neurons of the anterior horns [16] and transcriptional activity
is also supported by the detection of SOCS3+ neurons [21]. Nuclear pSTAT3 and SOCS3 has
been also detected in microglia/macrophage during the acute phase of injury [16, 21] and
nuclear pSTAT3 in oligodendrocytes and astrocytes during the first week near the lesion site
[12, 22]. Due to a prominent role in glial scar formation, spatial STAT3 activation on astro‐
cytes has also been highly defined. It has been determined that during the first week pSTAT3+
astrocytes appear at the border of the lesion with elevated predominance on the first 500 μm
near the injury [12, 22].
After the first week of injury, contusion models show chronic pSTAT3 signalling in glial cell
types located in the lesion borders. pSTAT3 has been detected in oligodendrocyte precursor
cells (OPCs) and oligodendrocytes at 2 wpi [18, 19]. This activation decreases from 1 to 5 wpi,
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but at that time is still higher than on uninjured spinal cords [19]. pSTAT3+ astrocytes have
been detected even further, at 12 wpi in the lesion borders [19].
4. Role of JAK-STAT in axon regeneration and collateral sprouting
To recover motor function after SCI, new connections have to be established after neuron death
and axon degeneration [2]. These circuits can be established by two different cellular respons‐
es that should not be confused: Axon regeneration is the process where axons from severed
neurons regrow from the injured tip or from a lateral growth distant to the injury (Figure 2a-
b). On the contrary, collateral sprouting is a compensatory growth from undamaged axons
initiated in response to injury (Figure 2c) [23].
While there is limited axon regeneration through the lesion area in response to complete SCI
(Figure 2a), there is a compensatory remodelling on brain and spinal circuits when the spinal
Figure 2. Axonal regeneration and collateral sprouting in spinal cord injury. Models used to evaluate axon regenera‐
tion and circuit remodeling, showing corticospinal tract (CST, in blue) as an example. Remodeling can be evaluated by
axonal regeneration or collateral sprouting (both in red arrows) and new innervations can be connected to propiospi‐
nal neurons (PSNs, interneurons in orange) or motor neurons (in green). CNS injury is indicated as a darkened triangle
in every model. A, In SCI models (usually contusion and hemisection) axonal regeneration of injured CSTs can be eval‐
uated through and beyond the lesion area. B, in a hemisection model, innervation of new targets by injured CSTs can
be evaluated. Regenerative axons from CSTs can innervate PSNs, which then connect to denervated motoneurons. C,
in a unilateral pyramidotomy injury paradigm, collateral sprouting of uninjured CSTs to denervated PSNs and motor
neurons can be measured. Anterograde, retrograde or retrograde trans-synaptic labelling are used depending of the
injury model.
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cord lesion is incomplete [2]. The corticospinal tract (CST) has been used as a model to study
this recovery process. CST starts in the motor cortex and connects to spinal motor neurons,
controlling voluntary motor function [23]. After spinal cord injury, CST circuit remodelling
can be achieved by axon regeneration innervating long descendent interneurons that in‐
crease connection to motoneurons (Figure 2b) [24] or by collateral sprouting of uninjured axons
to denervated motoneurons (Figure 2c) [25]. In this section we will discuss the role of JAK-
STAT pathway on the promotion of axon regeneration and collateral sprouting after SCI.
Briefly, we will discuss the results involving dorsal root ganglion (DRG) and optic nerve injury,
to follow with studies of axon growth and collateral sprouting of the CSTs after SCI.
4.1. Role of JAK-STAT pathway in axon regeneration in SCI and other nerve injury models
4.1.1. Axon regeneration after dorsal root ganglion or optic nerve axotomy
The DRG model has been useful to study axon regeneration due to regenerative and non-
regenerative branches. Sensory neurons from DRG target peripheral tissue with branches (i.e.
sciatic nerve) that regenerate after axotomy. On the contrary, DRG neurons also target the
dorsal column of the spinal cord, which do not regenerate after injury. This difference in the
regenerative capacity has been partially related to the JAK-STAT pathway activation by studies
on cytokine deficient mice, but conclusive results have been obtained in a study assessing the
role of STAT3 in axon regeneration. While STAT3 deletion reduced axon growth of the severed
sciatic nerve, STAT3 viral over-expression in the DRG improves axon regeneration of the non-
regenerative nerve [26].
Similar to the activation of the JAK-STAT pathway in the DRG model, axon growth has been
also promoted in the non-regenerative optic nerve. JAK-STAT activation by CNTF treatment
or deletion of the SOCS3 negative feedback improved axon regeneration in optic nerve
injury [11]. The studies in both injury models demonstrate that the JAK-STAT pathway,
specifically the axis of STAT3/SOCS3, promotes axon regeneration. Therefore, a possible
mechanism to improve motor recovery after SCI is through modulation of the JAK-STAT
pathway to induce axon regeneration.
4.1.2. Axon regeneration after the spinal cord injury
A hemisection study showed that only a small subset of cortical neurons presented an
increment in STAT3 and pSTAT3 levels after SCI, suggesting that on the contrary of periph‐
eral nerves, in the spinal cord there is a lack of retrograde JAK-STAT activation [27]. As in DRG
and optic nerve injury models, insufficient JAK-STAT activation could be related to the lack
of axon regeneration. Several studies have shown that improvement of local extrinsic factors,
such as cytokines administration, or improvement of intrinsic factors, such as the genetic
modulation of the JAK-STAT pathway in neurons, improves axon regeneration after SCI,
suggesting that modulation of JAK-STAT can be a bona fide target for designing novel
therapies for spinal cord repair.
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Administration of CNTF, G-CSF (granulocyte-colony stimulating factor), IL6 and LIF by
intrathecal or i.p. injections results in improved axon regeneration through the lesion site and
motor recovery after SCI. CNTF intrathecal injections during the first 10 days or administration
in sodium-hyaluronate particles placed in the transection site have improved functional
recovery after SCI [28, 29]. Although CST axon regeneration has not been assessed in CNTF
treatment, a study showed increased retrograde labelling of the rubrospinal tracts [28].
Another study showed improved axonal sprouting through the lesion site, although it was not
evaluated if these axons were from local neurons or descended from the brain [29].
Axon regeneration has also been assessed after spinal cord administration of G-CSF during 2
weeks after a hemisection [30]. CST axon regeneration was improved in the lesion site although
no axon growth caudal to the injury was detected. The local G-CSF delivery also results in
improvement of motor function and a similar result was observed in a transgenic mice line
expressing G-CSF under the control of the MapKII promoter that is specifically activated in
cortical and spinal cord neurons [30].
On the contrary to CNTF and G-CSF treatments, LIF has been administered daily by intraper‐
itoneal injection since it is actively transported through the BBB with a mechanism involving
the LIFRα receptor [31, 32]. LIF treatment for 14 days in a hemisection injury model im‐
proved the number of retrograde labelled CST and rubrospinal neurons. Improvement in
motor recovery was assessed by RotaRod and Platform hang tests [32].
Although CNTF, G-CSF and LIF treatments showed an improvement in axon regeneration
and motor function in rodents, in these studies the activation of the JAK-STAT pathway in
cortical neurons was not assessed. Besides, these studies cannot distinguish if the improve‐
ment in axon regeneration and functional recovery is due to the modulation of the intrinsic
program of cortical neurons or due to the modulation of other spinal cord cell types. Contrary
to these studies, local IL6 administration has been shown to activate the JAK-STAT pathway
in spinal and cortical neurons [33, 34]. IL6 intrathecal administration during the first week after
a hemisection injury increased pSTAT3 levels in the spinal cord and in cortical neurons, while
up-regulated the regeneration associated gene GAP-43 mRNA [34]. Although no motor
recovery analyses were assessed, anterograde labelling showed an increase in the number of
synapsin1+ CST axons near the lesion site [33].
The IL6 treatment suggests that cytokine delivery can promote the regenerative response of
motoneurons by JAK-STAT pathway activation. In addition, specific STAT3 over-expression
in the cortex has shown that this pathway can promote axon regeneration. After over-
expression mediated by adenovirus injection in the cortex, pSTAT3 levels increased in cortical
neurons and CST axonal regeneration improved through and beyond the lesion site of a
hemisection [27].
4.2. Role of JAK-STAT in circuit remodelling by collateral sprouting
Although improvement in axon regeneration (Figure 2a) and motor recovery has been
achieved by cytokine delivery, no relation has been established between the observed axon
regeneration in the lesion site and the motor recovery. On the contrary, studies involving JAK-
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STAT pathway and circuit remodelling by collateral sprouting (Figure 2c) have suggested that
motor recovery is accomplished by innervation of uninjured axons to denervated motoneur‐
ons and interneurons.
Cytokine Treatment Cell response Motor recovery References
Il6 Acute by i.t. Axon regeneration Not assessed [33, 34]
Acute i.p., MR16-1 Immune modulation Improved [66, 84, 85]
LIF 10-14 days by i.p. Axon regeneration
Glial modulation
Improved [32, 60, 61]
CNTF 10 days by i.p. or
Hyaluronate
Axon regeneration
Glial modulation
Improved [28, 29]
SC viral expression Collateral sprouting Not assessed [13]
OSM Gel foam Glial modulation Improved [15]
G-CSF 2 weeks by i.t. Axon regeneration
Neuroprotection
Improved [30]
Acute by subcutaneous, i.v. or i.t. Neuroprotection
Glial modulation
Immune modulation
Improved [40, 54-57, 81]
GM-CSF Acute by i.v., i.t. or i.p. Glial modulation Improved [54, 55, 64]
EPO Acute by i.p. Collateral sprouting
Glial modulation
Improved [35, 58, 59]
IL10 Acute by i.p. Glial modulation
Immune modulation
Improved
Not improved
[77, 78]
SC viral expression Neuroprotection Improved [48, 49]
IL12 Gel foam Glial modulation
Immune modulation
Not improved [82]
Table 2. Pre-clinical studies with cytokine for motor recovery of SCI. Summary of JAK-STAT cytokine preclinical
studies, for any cytokine it is shown administration timing and method. Time indicated as acute means a single dose at
the moment of injury or daily doses from 1 to 5 dpi. Methods of administration are indicated as intrathecal (i.t.),
intraperitoneal (i.p.), intravenous (i.v.) or subcutaneous injection; embedded on hyaluronate or gel foam placed in the
lesion site; and by SC (spinal cord) viral expression. Contrary to the other studies, MR16-1 indicates a treatment with a
neutralizing antibody against IL6 receptor.
Promotion of collateral sprouting by the hematopoietic cytokine EPO (Erythropoietin) has
been assessed in a model of traumatic brain injury that results in denervation of the CST circuit.
EPO i.p. injections during the acute phase resulted in increased collateral sprouting of
uninjured CST fibers in the cervical and lumbar area and improved motor function [35].
Although it has not been shown that EPO activate the JAK-STAT signalling pathway in
neurons, cortical viral infection has been useful to determine the role of the pathway in
collateral sprouting. STAT3 viral over-expression in uninjured mice induced collateral
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sprouting and innervations to propiospinal neuron (PSN, a type of interneuron) [27]. This viral
expression was also assessed in a unilateral pyramidotomy model, which is an injury at the
level of the medulla oblongata that severs half of the CST (Figure 2c) and it is useful to evaluate
how collateral sprouting connects to spinal neurons. In this approach it was shown that STAT3
induced collateral sprouting, innervation of PSNs and motoneurons, and improvement in
motor recovery which was assessed by behavioural and electrophysiological tests [27]. Cortical
SOCS3 deletion also induced collateral sprouting in the pyramidotomy paradigm [13],
suggesting that an endogenous JAK-STAT pathway activation promotes circuit remodelling.
After finding a transient CNTF expression in denervated neurons caudal to injury, the same
study showed that combination of cortical SOCS3 deletion and spinal cord CNTF over-
expression improved collateral sprouting [13].
5. Role of JAK-STAT in local neuron response
In response to SCI the number of local motor and interneurons decrease with no neurogene‐
sis to generate new neurons [2]. To improve motor recovery, promotion of axon regenera‐
tion and collateral sprouting should be accompanied by neuroprotective strategies, since
number and dendrite distribution of local spinal neurons would be beneficial for circuit
remodelling. We will start this section discussing in vitro studies related to the neuroprotec‐
tive role of the JAK-STAT pathway, following in vivo studies with cytokine delivery and
knockdown treatments after SCI.
5.1. Role of JAK-STAT in neuron survival
At a molecular level, studies in non-neural cells have shown that STAT transcription factors
have different roles in apoptosis regulation. A comparative in vitro study of STAT1 and STAT3
showed that while STAT1 inhibits the expression of the anti-apoptotic genes Bcl-2 and Bcl-X,
STAT3 promoted their expression [36]. STAT5 proteins, which are activated by a different set
of cytokines (Table 1), also promote cell survival by Bcl-X upregulation [37].
In vitro studies have shown that the neuroprotective role of JAK-STAT cytokines is partly
associated to STAT3 activation and expression of anti-apoptotic genes. IL10 activated STAT3
and promoted Bcl-2 and Bcl-xl expression in embryonic spinal cord neurons [38]. IL6 and OSM
cytokines also activated STAT3 and promoted anti-apoptotic gene expression in cortical
neurons and neuroblastoma cells [39]. In cultured cerebellar granule neurons, G-CSF also
promoted STAT3 activation while increased Bcl-2 levels [40]. It should be considered that
theses cytokines also activate the AKT pathway [39, 40]. Both inhibition of the JAK and AKT
pathway decreased the neuroprotective effect, suggesting that probably both pathways
contribute to the anti-apoptotic response [38, 40].
Related to the previous in vitro studies, in vivo studies in CNS injury suggest a protective role
of STAT3 while an opposite role for STAT1. On a focal cerebral ischemia model, it was shown
that STAT1 deficient mice presented a reduced infarct size and apoptotic cell number [41]. On
the contrary, on a permanent cerebral ischemia model the IL6/STAT3 axis has been associat‐
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ed to positive outcomes. While the neutralization with an anti-IL6R antibody resulted in
decreased STAT3 activation and increased lesion area, IL6 administration reduced the lesion
size [42, 43]. Although these studies indicate a neuroprotective role of STAT3, specific cell type
modulation should be assessed to differentiate the direct modulation on neuron response from
indirect neuroprotection by modulation of glial and inflammatory cell types. At this mo‐
ment, there is only one study where specific STAT3 deletion in neurons is analyzed in an in
vivo CNS injury model. Mice with STAT3 deletion in neurons (using the Neurofilament L
promoter) showed a decrease in motoneuron number after facial nerve injury and diminish‐
ed expression of anti-apoptotic genes [44].
5.2. JAK-STAT modulation of neuronal protection in SCI
G-CSF and IL10 are cytokines with several studies showing beneficial outcomes in neuropro‐
tection, inflammatory response and motor recovery after SCI [45, 46]. It has been shown that
a pro-inflammatory response is negative for neuron survival [47]; therefore, in these cyto‐
kine treatments it is difficult to differentiate a direct modulation on neuronal survival and the
effect on neuro-inflammation. Since it has been shown that spinal cord neurons express G-CSF
and IL10 receptors [40, 48], we will discuss a small set of studies that focused in neuroprotec‐
tion and in a following section we will discuss the modulation of the immune response in SCI.
G-CSF has been locally administrated to evaluate neuroprotection in SCI. Subcutaneous G-
CSF treatment during the first five days after compression improved motor recovery,
decreased apoptotic neurons in the acute phase and improved neuron number in the remod‐
elling phase (6 wpi) [40]. Other studies with intrathecal administration of G-CSF for 2 weeks,
commented before for assessing axonal regeneration, also showed neuroprotective results.
This long-term treatment reduced apoptotic cell number and increased Bcl-xL expression in
the spinal cord [30]. Two independent IL10 viral over-expression studies also improved motor
function [48, 49] and one of these studies showed decreased pro-apoptotic protein levels and
increased Bcl-2 levels, resulting in a higher neuron number [48]. Although it was shown by in
vitro studies that G-CSF and IL10 treatments activate STAT3 in spinal neurons [40, 48], it has
not been demonstrated that this activation occurs on in vivo treatments. In vivo analyses of IL10
over-expression only focused in neuronal NF-κβ activation [48]. Therefore, it is an open
question if these cytokines promotes neuron survival by JAK-STAT activation or by other
signalling pathway, as NF-κβ gene regulation.
Although by results of cytokine treatments the role of STAT3 in neuroprotection remains
inconclusive, knockdown of the inhibitory protein SOCS3 has contributed to this proposi‐
tion [21]. Local over-expression of shSOCS3 diminished SOCS3 mRNA levels. This knock‐
down increased pSTAT3 levels in a transection model and it decreased the Bax/Bcl-2 protein
ratio, while improving neuron number near the lesion site [21]. A following study of the same
group showed that SOCS3 knockdown increased dendrite growth in dorsal and ventral horns
near the injury site [50].
Finally, consistent with the pro-apoptotic role of STAT1 on in vitro studies [36], STAT1
knockdown has shown positive outcomes after SCI. Administration of STAT1 siRNA reduced
STAT1 protein levels in the spinal cord. Although no analysis of neuronal survival was
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assessed, 1 day post-contusion the STAT1 knockdown mice had increased its Bcl-2 levels.
siRNA treated mice also improved motor function assessed by BMS open-field score.
6. Role of JAK-STAT in glial response
In response to SCI, apoptosis of astrocytes and oligodendrocytes occurs in the acute phase of
injury and then glial cells dynamically respond during weeks and months after injury. A glial
hallmark of CNS injury is the glial scar, formed by reactive astrocytes, OPCs and meningeal
cells [51]. This compact scar gathers around damaged tissue, inflammatory cells and fibro‐
blasts. The glial scar is necessary to contain secondary injury, as disruption of the astrocyte
scar with different transgenic models leads to increased cell death, demyelination and reduced
functional motor recovery [12, 52, 53]. Although the glial scar is necessary for the contain‐
ment of the lesion, reactive astrocytes express and secrete inhibitory molecules for axonal
growth and sprouting, as chondroitin sulfate proteoglycans (CSPGs) [51]. Altogether with the
glial scar formation, a demyelination process occurs during weeks after injury by oligoden‐
drocyte apoptosis. Although mature oligodendrocytes do not proliferate to recover cell
number, OPCs start to proliferate and differentiate and remyelination proceeds near the lesion
area [6]. Accordingly to the glial response commented above, in this section we will discuss
the following topics: Cytokine modulation of the glial response to reduce secondary damage,
the regulation of reactive astrocyte and the neural stem progenitor cells (NSPCs) by the STAT3/
SOCS3 axis.
6.1. Cytokines modulate glial response in SCI
Several studies with the hematopoietic and IL6-family cytokines have assessed astrocyte and
oligodendrocyte responses with positive outcomes on tissue preservation and motor recov‐
ery. Acute administration of GM-CSF or G-CSF by i.p. or i.v. injections during the acute phase
reduced lesion area, while increasing the spared myelin area and improving motor recovery
after SCI [54–56]. Both cytokine treatments reduced NG2 levels (OPC marker) during the first
week of injury [54, 55]. In one of these studies it was also shown that G-CSF up-regulated Bcl-
xL and reduced apoptosis in oligodendrocytes [56]. Therefore, these results suggest that these
cytokines maintain spared myelin by a protective mechanism and not by promotion of OPC
proliferation.
GM-CSF and G-CSF also modulate the reactive astrocyte response during the first month after
SCI, as seen by the reduction of GFAP levels and the CSPG neurocan [54, 55]. Another study
with improvement in motor recovery by G-CSF intrathecal administration during the first day
of injury also showed a reduction in the CSPG proteins neurocan and phosphocan [57].
Altogether with the previous studies, this last study suggest that G-CSF decrease the reac‐
tive gliosis because the treatment reduced TGF-β levels, a growth factor that promotes reactive
gliosis; reduced vimentin levels, an astrocyte filament induced in glial scar; and presented less
astrocyte proliferation [57]. Acute EPO i.p. injection also has similar results in astrocyte
regulation after SCI. EPO treatment reduced lesion area and GFAP levels, while improving
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preservation of myelin and motor recovery at 2 wpi [58]. A following study showed possible
differences with GM-CSF and G-CSF on the OPC response. Although these cytokines reduce
NG2 levels, it was shown that EPO treatment increased it at 4 wpi [59].
The IL6-family of cytokines also regulates glial response. LIF i.p. administration has been
shown to reduce oligodendrocyte apoptosis [60, 61], although in vivo LIF signalling on
oligodendrocyte is not clear. On one hand, one study found that SCI induced LIFRβ expres‐
sion on oligodendrocytes and that LIF treatment induced pSTAT3 and pAKT in these cells [60].
On the contrary, an alternative study did not find LIFRβ expression on oligodendrocytes and
suggested a LIF positive modulation of microglia [61]. Although studies with LIF i.p. treat‐
ment have not assessed the astrocyte response in SCI, it has been shown that this treatment
incremented Nestin+ cell number near the lesion site [32]. CNTF treatment, previously
commented for improved motor recovery and axon regeneration, also increased the density
of astrocytes [28]. Finally, gel foam administration of OSM reduced the lesion area and
preserved MBP (myelin basic protein), but on the contrary to the other IL6-family cytokines,
it reduced GFAP levels near the lesion site. This glial modulation was accompanied by
improved serotonergic fiber outgrowth and motor recovery [15].
6.2. STAT modulation of reactive astrocytes
Contrary to motoneuron response in SCI, astrocyte response has been studied with cell-specific
deletions of STAT3 and SOCS3. Deletions on Nestin or GFAP expressing cells, two genes up-
regulated in reactive astrocytes, have elucidated the role of the JAK-STAT signalling path‐
way on reactive gliosis. Mice with Nestin:STAT3KO or GFAP:STAT3KO had an increased
lesion area and decreased glial scar after 2 weeks of a contusive SCI [12, 22]. Consistent with
the protective role of the glial scar, this was accompanied by increased demyelination and
inflammatory response, altogether with a lack of motor recovery after injury. On the contra‐
ry, the deletion of the negative feedback in a Nestin:SOCS3KO mice had prolonged and
increased pSTAT3 levels in response to SCI, resulting in reduced lesion area, early and
increased glial scar surrounding this area, and improved motor recovery [12].
These in vivo studies demonstrated that the glial JAK-STAT signalling is necessary for
secondary damage contention and further studies have elucidated the cellular mechanisms
modulated by this pathway. First, it seems that JAK-STAT pathway is necessary for astro‐
cyte survival in response to injury, as an in vitro study showed that GFAP:STAT3KO astro‐
cytes had increased necrosis and protein release after a mechanical injury [62]. Besides cell
survival, JAK-STAT controls gene expression associated to reactive gliosis. STAT3 controls the
expression of glial filaments, as it is known that GFAP is a target gene for STAT3 [63] and in
GFAP:STAT3KO mice, reduced levels of GFAP and vimentin were detected [22]. Cell
morphology is also modulated by JAK-STAT pathway. In response to SCI, astrocytes near the
lesion site change their cell morphology and orientation to form the glial scar. In
GFAP:STAT3KO mice, astrocytes failed to change orientation and did not form the closed
boundaries of the glial scar [53].
Another STAT transcription factor that controls astrocyte response is STAT5, which is
activated by GM-CSF. As commented before, this cytokine reduced GFAP and CSPG levels
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with an increase in motor recovery [55]. An in vitro study with astrocytes activated with TGF-
β3, which up-regulates CSPG proteins, found that GM-CSF increased pSTAT5, pAKT and pRaf
levels [64]. The cytokine also reduced TGF-β signalling and CSPGs expression. GM-CSF effects
were blocked by JAK and PI3K inhibitors, suggesting that STAT5 and PI3K signalling could
reduce the levels of axon inhibitory proteins secreted by reactive astrocytes [64]. Following
studies should clarify if STAT5 has a similar role in vivo.
6.3. JAK-STAT modulation of neural stem progenitor cells
Adult neural stem progenitor cells (NSPCs) can generate new astrocytes and oligodendro‐
cytes in homeostasis and in response to injury [5, 6]. NSPCs can also generate new neurons
but only in some CNS specific areas, the dentate gyrus and the subventricular zone (SVZ) [65].
The role on the JAK-STAT pathway to modulate neurogenesis and gliogenesis is not clear and
probably depends on the specific context, the cytokine types and cellular phenotype. At one
hand, in vitro studies show that the JAK-STAT pathway induces gliogenesis in opposition to
neurogenic differentiation, as seen in the blocking of IL6/STAT3 axis in NSPCs [66, 67]. On the
other hand, there are some in vivo studies that have shown a JAK-STAT role for specific
cytokines in adult NSPC proliferation and neurogenesis. In the dentate gyrus, CNTF and
STAT3 deficient mice had reduced NSPC proliferation and neurogenesis [68]. Using cyto‐
kine injections and deficient mice it has been also shown that IL15 and IL10 regulate NSPC
proliferation in the SVZ [69, 70].
Contrary to the neurogenesis of the dentate gyrus and the SVZ, in the spinal cord there is only
gliogenesis. This cell differentiation occurs in three main cell types that proliferate in re‐
sponse to injury: ependymal cells, astrocytes and OPCs [6]. The role of the JAK-STAT pathway
on proliferation and differentiation of ependymal cells and astrocytes has not been assessed,
as transgenic mice with specific cell type deletion has been done only for Nestin and GFAP
promoters, which are markers for both NSPCs and mature astrocytes. On the contrary,
understanding on OPCs modulation has been done in vivo by NG2 knockout cells [71]. In
response to injury, NG2+ cells proliferate and increase in number near the lesion site. NG2
proliferation is incremented in a NG2:SOCS3KO mice. On the contrary, in the NG2:STAT3KO
mice no differences in NG2 cell number and proliferation were detected [71]. This could be
explained by the modulation of OPC proliferation by other STAT transcription factors or by
other pathways activated by JAK proteins (Figure 1), which are inhibited by SOCS3. JAK-STAT
modulation of NG2 cell differentiation was also assessed in this study. Although STAT3 did
not regulate OPC proliferation, in the same study it was shown that NG2:STAT3KO mice had
reduced differentiation to mature oligodendrocytes during the first week of injury, but not at
chronic phases (1mpi) [71].
7. Role of JAK-STAT in the inflammatory response
In response to injury neutrophils, macrophages and lymphocytes infiltrate to the spinal cord
[72]. There are several studies where reduction of cell infiltration improves motor recovery
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and tissue sparing [73, 74]. Even so, the reduction of functional recovery after SCI in mice with
total ablation of infiltrated macrophages indicates that the inflammatory response is also
necessary for proper recovery [75]. These differences could be explained taking into account
that immune cells have different and opposite phenotypes. Microglia and macrophages, the
main effectors during spinal cord inflammation, are capable of polarization that leads to either
pro-inflammatory (M1 type) or anti-inflammatory cells (M2 type). While M1 macrophages
participate in secondary damage as well as in axonal retraction observed after SCI, M2
macrophages are proposed to be protective and promote axonal growth [47]. Considering the
role of cytokines in the regulation of the immune response, in this section we discuss studies
where JAK-STAT signalling has been shown to reduce the inflammatory response or change
macrophage phenotype for improvement in spinal cord functional recovery.
7.1. Anti-inflammatory cytokines
IL10 is a cytokine that has been studied in SCI for anti-inflammatory modulation and
neuroprotection [46]. Endogenous IL10 expression has not been assessed in detail after SCI
and it is only known that M2 infiltrated macrophages express Il10 surrounding the glial scar
[75]. Using IL10 deficient mice it has been found that this cytokine is necessary for control‐
ling the inflammatory response and apoptosis. After SCI, IL10 deficient mice have an in‐
creased expression of pro-inflammatory genes, increased levels of the pro-apoptotic proteins
and decreased motor recovery [76]. Another study which replaced normal monocytes with
IL10 deficient monocytes also resulted in reduced motor recovery, suggesting that this
cytokine is necessary for the positive macrophage anti-inflammatory response [75]. IL10
treatments in SCI has resulted in motor recovery improvement by inflammatory and neuro‐
protective regulation. Acute i.p. administration of IL10 reduced lesion volume in two
independent studies [77, 78]. But while one study showed that IL10 improved motor recov‐
ery and reduced TNFα expression in the injured spinal cord and in infiltrated macrophages
[77], the other study did not find any functional recovery [78]. Although we previously
commented other studies with motor recovery improvement by local viral over-expression of
IL10 [48, 49], on those studies the inflammatory response was not assessed.
Another important anti-inflammatory cytokine is IL4, which signals by the STAT6 transcrip‐
tion factor. Although the neutralization of this cytokine by anti-IL4 antibody administration
increased the inflammatory response, neither the IL4-neutralization treatment nor a study with
STAT6 deficient mice found differences in motor recovery after SCI [79, 80]. These results
indicate that Il4 signalling is not necessary for motor recovery. Further studies should test this
cytokine in the promotion of the anti-inflammatory response in SCI.
In addition, there are some G-CSF studies which have shown immune modulation upon SCI.
Previously commented studies for G-CSF modulation on glial cells also assessed immune
response. Daily intravenous administration of G-CSF during the first 4 dpi showed that
treatment not only improved motor recovery and oligodendrocyte protection, but also
suppressed upregulation of the pro-inflammatory cytokines TNFα and IL1β and reduced IL1β
+ neutrophils infiltration [56]. Another treatment with G-CSF intrathecal injection during the
first day reduced macrophage/microglia cell number and TNFα levels during the first 2 wpi
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[57]. Although G-CSF is well known for neuroprotective modulation [45], only one study has
elucidated a biological mechanism for G-CSF inflammatory modulation on SCI. While in this
study was found an increase in microglial number at 7dpi in the G-CSF treated mice, in vitro
analyses indicated that this cytokine induced a M2 microglial phenotype, reducing pro-
inflammatory genes while inducing IL10 expression [81]. A further characterization should be
done to demonstrate that G-CSF induces a M2 phenotype in vivo.
7.2. Pro-inflammatory cytokines
IL12 is a pro-inflammatory cytokine produced by macrophages and dendritic cells which
signals via STAT4 [82]. Although it was shown that gel foam administration of IL12 regulat‐
ed immune and OPC response, this treatment slightly improved motor recovery in C57BL/6
mice and did not improve function in BALB/c strain [83]. A similar result was found after SCI
in STAT4 deficient mice, no improvement was found in comparison WT mice [79]. These
studies suggest that IL12 signalling is not functionally important for motor recovery.
The IL6-cytokine family has shown different effects in inflammatory response after spinal cord
injury. IL11 deficient mice have been assessed in SCI, with no significant differences in motor
recovery or macrophage infiltration [17]. LIF treatment incremented Mac1 levels, a marker for
macrophage/microglial, and IGF-1 expression on these cells [61], while gel foam administra‐
tion of OSM reduced T-cell infiltration [15]. Although we previously discussed IL6 intrathe‐
cal administration for axon regeneration modulation [33, 34], IL6 is a pro-inflammatory
cytokine which can be blocked to decrease inflammatory response. To avoid Il6 mediated
immune response, a single i.p. administration of MR16-1, an anti-mouse IL6 receptor anti‐
body, has been tested with positive outcomes. MR16-1 improved motor recovery after a
contusive SCI [66, 84]. This treatment also reduced the lesion area, astrocyte proliferation and
increased spared myelin area and neurofilament and serotonergic fibers near the lesion area
[66, 85]. The mechanism underlying the MR16-1 improvement in tissue and functional
recovery has been associated to microglial and infiltrated macrophage function. MR16-1
accelerated inflammatory resolution, as number of total macrophage/microglial began to
decrease earlier in the treated group [85]. Further phenotypic characterization of immune cells
lead to the discovery that in MR16-1 treated mice, the microglial cells had an increased
phagocytic phenotype. It was also shown that macrophages had a predominant M2 pheno‐
type and that anti-inflammatory cytokines were up-regulated while pro-inflammatory
cytokines were down-regulated [84, 85].
8. Conclusion and clinical implications
Cytokine upregulation and JAK-STAT signalling activation are endogenous mechanism that
are activated in response to SCI and can be used to improve motor recovery. Cell type specific
and in vitro studies have identified the role of STATs modulation in spinal cord cells. STAT3
has been the most extensively studied STAT transcription factor in SCI, but promising results
have been found in other STATs and further studies should continue to determine the roles of
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STAT1 and STAT5 in SCI. Moreover, further studies with transgenic models should focus in
other specific cell responses not studied up to now, like motoneuron and NSPC responses.
Several preclinical studies have shown positive outcomes for motor recovery and tissue
sparing in JAK-STAT cytokine treatments (Table 2). Thus, modulation of the JAK-STAT
signalling presents an opportunity to modulate neuron and glial response after an SCI in
clinical settings. The hematopoietic cytokines have been already used in clinical studies for
several pathologies, therefore are advanced in comparison with other JAK-STAT cytokines.
Discussion of G-CSF and EPO treatments for SCI can be found in previous chapters [45, 86],
while for GM-CSF there is one SCI clinical study finished which consisted in cytokine
administration with transplant of bone marrow cells [87]. Although clinical studies have not
been assessed for other cytokines in CNS trauma, there are clinical studies involving other
pathologies that could be translated to SCI. The anti-inflammatory and neuroprotective
mechanism of IL10 could also be assessed with a recombinant human IL10 that has been used
for HIV infection and other several pathologies [46]. Emfilermin is a recombinant human LIF
that has been tested, although with a lack of effectiveness, in clinical trials for embryo
implantation and peripheral neuropathy [88, 89] that could also be used in SCI or other CNS
diseases. Finally, tocilizumab, an anti-human IL6R, has shown positive outcomes in clinical
studies for rheumatoid arthritis [90] and could be used for anti-inflammatory treatment in the
spinal cord acute response.
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